Merck’s V116 Pneumococcal Conjugate Vaccine Shows Positive Data in Phase 3 Studies

Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, has shown positive data from multiple Phase 3 studies, offering potential clinical value to a range of adult populations. The vaccine has been found to be immunogenic for all 21 serotypes covered by the vaccine in various adult populations, including those at an increased risk of pneumococcal disease. If approved, V116 would be the first pneumococcal conjugate vaccine designed specifically for adults, providing confidence in its potential clinical value.